All Releases
  Theravance Announces Proposed Public Offering of Common Stock
Mar 17, 2010 		PDF 27.1 KB Add to Briefcase
  Theravance Announces New Employment Inducement Awards
Mar 1, 2010 		PDF 20.8 KB Add to Briefcase
  Theravance to Present at Investor Conferences in March 2010
Feb 25, 2010 		PDF 21.0 KB Add to Briefcase
  Theravance Reports Fourth Quarter and Full Year 2009 Financial Results
Feb 11, 2010 		PDF 157.5 KB Add to Briefcase
  Theravance to Report Fourth Quarter and Full Year 2009 Financial Results on February 11, 2010
Feb 3, 2010 		PDF 11.6 KB Add to Briefcase
  Theravance Announces New Employment Inducement Awards
Feb 1, 2010 		PDF 11.1 KB Add to Briefcase
  Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Jan 28, 2010 		PDF 33.1 KB Add to Briefcase
  Theravance to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 7, 2010 		PDF 22.1 KB Add to Briefcase
  Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
Dec 2, 2009 		PDF 22.1 KB Add to Briefcase
  Theravance Announces New Employment Inducement Awards
Dec 1, 2009 		PDF 20.1 KB Add to Briefcase
  Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
Nov 30, 2009 		PDF 26.3 KB Add to Briefcase
  Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Nov 27, 2009 		PDF 31.0 KB Add to Briefcase
  Theravance and Astellas Announce the Commercial Launch of VIBATIV( TM ) (telavancin) in the United States
Nov 5, 2009 		PDF 30.3 KB Add to Briefcase
  Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
Nov 3, 2009 		PDF 22.0 KB Add to Briefcase
  Theravance Announces New Employment Inducement Award
Nov 2, 2009 		PDF 20.1 KB Add to Briefcase
  Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
Oct 28, 2009 		PDF 28.9 KB Add to Briefcase
  Theravance Reports Third Quarter 2009 Financial Results
Oct 27, 2009 		PDF 156.3 KB Add to Briefcase
  GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
Oct 27, 2009 		PDF 36.4 KB Add to Briefcase
  Theravance Earns $20 Million Milestone Under Telavancin Collaboration Agreement
Oct 22, 2009 		PDF 31.7 KB Add to Briefcase
View Summary Theravance to Report Third Quarter 2009 Financial Results on October 27, 2009
Oct 19, 2009 		PDF 9.3 KB Add to Briefcase
Showing 1-20 of 203 Page: 1 2 3 ... 11  Next 20
= add release to Briefcase
©2010 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.

VIBATIV is a trademark of Astellas Pharma Inc.

RELOVAIR is a trademark of Glaxo Group Ltd.

Terms of Use     Website Admin Contact     Theravance Contact     Site Map